Pervasive Developmental Disorder Clinical Trial
Official title:
Pharmacotherapy of Pervasive Developmental Disorders
The purpose of this study is to develop a better tolerated and more effective pharmacologic treatment with individuals with Pervasive Developmental Disorder. This is a double-blind, placebo-controlled study of aripiprazole in the management of the maladaptive behaviors of Pervasive Developmental Disorder. The investigators hypothesize that aripiprazole will be more effective than placebo for reducing aggression, tantrum and self-injurious behavior in children with Pervasive Developmental Disorder.
Pervasive developmental disorders (PDDs) are characterized by severe impairments in social interaction and communication in addition to restricted patterns of interests and activities. Research suggests that a dysregulation of the dopamine and serotonin systems contributes to these interfering behaviors in individuals with PDD. After benefits of typical neuroleptics were reported in subjects with PDD, research shifted to the atypical antipsychotics which have been shown to be better tolerated and effective in this population. However, the atypical antipsychotics have also been associated with adverse effects. Thus there remains a need for a novel pharmacotherapy that would be safe and effective for children and adolescents with PDDs. The primary objectives of this study are to determine whether aripiprazole is effective and well tolerated for irritability in children and adolescents with PDD not otherwise specified (NOS) during an 8-week acute phase and whether the effectiveness and tolerability of aripiprazole is maintained during a 16-week continuation phase. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01243905 -
Group Psychoeducational Program for Mothers of Children With High Functional Pervasive Developmental Disorders
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT00531830 -
Assessment of Factors Which Predict Improvement in Children With PDD After a Year of Integrative Therapy
|
N/A | |
| Completed |
NCT02985749 -
A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
|
Phase 3 | |
| Terminated |
NCT00325572 -
Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism
|
Phase 1 | |
| Completed |
NCT00399698 -
Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.
|
Phase 3 | |
| Completed |
NCT03177590 -
Recording Facial and Vocal Emotional Productions in Children With Autism as Part of the JEMImE Project
|
N/A | |
| Recruiting |
NCT05664841 -
The Impact of a Virtual Magic Trick Training Program
|
Phase 2 | |
| Active, not recruiting |
NCT02199925 -
An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
|
Phase 4 | |
| Completed |
NCT00464477 -
Advanced Grandparental Age as a Risk Factor for Autism
|
N/A | |
| Terminated |
NCT01553240 -
Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies
|
N/A | |
| Active, not recruiting |
NCT03170453 -
Confirmatory Efficacy Trial of Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder
|
N/A | |
| Completed |
NCT00773812 -
Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders
|
Phase 1 | |
| Completed |
NCT01808066 -
GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs
|
N/A | |
| Completed |
NCT00198055 -
A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.
|
Phase 2 | |
| Completed |
NCT00308074 -
An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders
|
Phase 2 | |
| Completed |
NCT00579267 -
Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)
|
N/A | |
| Completed |
NCT04788537 -
Services to Enhance Social Functioning in Adults With Autism Spectrum Disorders
|
N/A | |
| Recruiting |
NCT04654260 -
Behavior Therapy for Irritability in Autism
|
N/A | |
| Completed |
NCT01921244 -
Shared Decision Making to Improve Care and Outcomes for Children With Autism
|
N/A | |
| Completed |
NCT00902798 -
Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder
|
N/A |